Reviews Anidulafungin


No reviews yet.

Eraxis Drug Description
ERAXIS™ 
(anidulafungin) For Injection
DRUG DESCRIPTION



What are the possible side effects of anidulafungin (Eraxis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling light-headed or faint; or
confusion, weakness, dry mouth, or muscle tenderness.

Less serious side effects may include:

hot flashes;
diarrhea or constipation;
nausea, vomiting, stomach...
Read All Potential Side Effects for Eraxis »




ERAXIS for Injection is a sterile, lyophilized product for
intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin)
is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus
nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs
that inhibits the synthesis of 1,3-β-D-glucan, an essential component of
fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4“-(pentyloxy)[1,1':4',1”-terphenyl]-4­yl]carbonyl]-L-ornithine]echinocandin
B. Anidulafungin is a white to off-white powder that is practically insoluble
in water and slightly soluble in ethanol. In addition to the active ingredient,
anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 
50mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125
mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for
pH adjustment. 
100mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250
mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid
for pH adjustment.
The empirical formula of anidulafungin is C58H73N7O17
and the formula weight is 1140.3.
The structural formula is:








Prior to administration, ERAXIS for Injection requires
reconstitution with sterile Water for Injection and subsequent dilution with
either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP
(normal saline). 
DO NOT dilute with other solutions or co-infuse with other
medications or electrolytes (see DOSAGE AND ADMINISTRATION).Last reviewed on RxList: 6/24/2009




Eraxis Drug Description
ERAXIS™ 
(anidulafungin) For Injection
DRUG DESCRIPTION



What are the possible side effects of anidulafungin (Eraxis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling light-headed or faint; or
confusion, weakness, dry mouth, or muscle tenderness.

Less serious side effects may include:

hot flashes;
diarrhea or constipation;
nausea, vomiting, stomach...
Read All Potential Side Effects for Eraxis »




ERAXIS for Injection is a sterile, lyophilized product for
intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin)
is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus
nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs
that inhibits the synthesis of 1,3-β-D-glucan, an essential component of
fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4“-(pentyloxy)[1,1':4',1”-terphenyl]-4­yl]carbonyl]-L-ornithine]echinocandin
B. Anidulafungin is a white to off-white powder that is practically insoluble
in water and slightly soluble in ethanol. In addition to the active ingredient,
anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 
50mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125
mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for
pH adjustment. 
100mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250
mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid
for pH adjustment.
The empirical formula of anidulafungin is C58H73N7O17
and the formula weight is 1140.3.
The structural formula is:








Prior to administration, ERAXIS for Injection requires
reconstitution with sterile Water for Injection and subsequent dilution with
either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP
(normal saline). 
DO NOT dilute with other solutions or co-infuse with other
medications or electrolytes (see DOSAGE AND ADMINISTRATION).Last reviewed on RxList: 6/24/2009




Eraxis Drug Description
ERAXIS™ 
(anidulafungin) For Injection
DRUG DESCRIPTION



What are the possible side effects of anidulafungin (Eraxis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling light-headed or faint; or
confusion, weakness, dry mouth, or muscle tenderness.

Less serious side effects may include:

hot flashes;
diarrhea or constipation;
nausea, vomiting, stomach...
Read All Potential Side Effects for Eraxis »




ERAXIS for Injection is a sterile, lyophilized product for
intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin)
is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus
nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs
that inhibits the synthesis of 1,3-β-D-glucan, an essential component of
fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4“-(pentyloxy)[1,1':4',1”-terphenyl]-4­yl]carbonyl]-L-ornithine]echinocandin
B. Anidulafungin is a white to off-white powder that is practically insoluble
in water and slightly soluble in ethanol. In addition to the active ingredient,
anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 
50mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125
mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for
pH adjustment. 
100mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250
mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid
for pH adjustment.
The empirical formula of anidulafungin is C58H73N7O17
and the formula weight is 1140.3.
The structural formula is:








Prior to administration, ERAXIS for Injection requires
reconstitution with sterile Water for Injection and subsequent dilution with
either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP
(normal saline). 
DO NOT dilute with other solutions or co-infuse with other
medications or electrolytes (see DOSAGE AND ADMINISTRATION).Last reviewed on RxList: 6/24/2009




Eraxis Drug Description
ERAXIS™ 
(anidulafungin) For Injection
DRUG DESCRIPTION



What are the possible side effects of anidulafungin (Eraxis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling light-headed or faint; or
confusion, weakness, dry mouth, or muscle tenderness.

Less serious side effects may include:

hot flashes;
diarrhea or constipation;
nausea, vomiting, stomach...
Read All Potential Side Effects for Eraxis »




ERAXIS for Injection is a sterile, lyophilized product for
intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin)
is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus
nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs
that inhibits the synthesis of 1,3-β-D-glucan, an essential component of
fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4“-(pentyloxy)[1,1':4',1”-terphenyl]-4­yl]carbonyl]-L-ornithine]echinocandin
B. Anidulafungin is a white to off-white powder that is practically insoluble
in water and slightly soluble in ethanol. In addition to the active ingredient,
anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 
50mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125
mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for
pH adjustment. 
100mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250
mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid
for pH adjustment.
The empirical formula of anidulafungin is C58H73N7O17
and the formula weight is 1140.3.
The structural formula is:








Prior to administration, ERAXIS for Injection requires
reconstitution with sterile Water for Injection and subsequent dilution with
either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP
(normal saline). 
DO NOT dilute with other solutions or co-infuse with other
medications or electrolytes (see DOSAGE AND ADMINISTRATION).Last reviewed on RxList: 6/24/2009




Eraxis Drug Description
ERAXIS™ 
(anidulafungin) For Injection
DRUG DESCRIPTION



What are the possible side effects of anidulafungin (Eraxis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling light-headed or faint; or
confusion, weakness, dry mouth, or muscle tenderness.

Less serious side effects may include:

hot flashes;
diarrhea or constipation;
nausea, vomiting, stomach...
Read All Potential Side Effects for Eraxis »




ERAXIS for Injection is a sterile, lyophilized product for
intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin)
is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus
nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs
that inhibits the synthesis of 1,3-β-D-glucan, an essential component of
fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4“-(pentyloxy)[1,1':4',1”-terphenyl]-4­yl]carbonyl]-L-ornithine]echinocandin
B. Anidulafungin is a white to off-white powder that is practically insoluble
in water and slightly soluble in ethanol. In addition to the active ingredient,
anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 
50mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125
mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for
pH adjustment. 
100mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250
mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid
for pH adjustment.
The empirical formula of anidulafungin is C58H73N7O17
and the formula weight is 1140.3.
The structural formula is:








Prior to administration, ERAXIS for Injection requires
reconstitution with sterile Water for Injection and subsequent dilution with
either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP
(normal saline). 
DO NOT dilute with other solutions or co-infuse with other
medications or electrolytes (see DOSAGE AND ADMINISTRATION).Last reviewed on RxList: 6/24/2009





Other reviews about Anidulafungin on wordpress

Anidulafungin: A Potent Antifungal that Targets Candida and Aspergillus.
  by JOC
Source: Infectious Diseases in Clinical Practice. 13(4):165-178, July 2005. Ghannoum, Mahmoud; D'Angelo, Maurissa Abstract: Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by travolta2
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by potapovweblog
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by pushkinblog
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by gipson28
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by phentermine38
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by tison03
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by jeison298
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Early clinical experience with anidulafungin at a large tertiary care medical center
  by xanaxpharm
Pharmacotherapy 28(1): 64-73 Abstract Study Objective. To evaluate early clinical experience with anidulafungin. Design. Retrospective cohort study. Setting. Large, university-affiliated, tertiary care medical center. Patients. All patients […]


Update in infectious disease treatment
  by JOC
Cleveland Clinic Journal of Medicine 2008; 75(8):584-590 DAVID L. LONGWORTH Studies published during the past year on the treatment of several infectious diseases provide valuable information that […]



Other reviews about Anidulafungin on web:

Anidulafungin or Eraxis (Ecalta in Europe) is an anti-fungal drug originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals. Anidulafungin - Wikipedia, the free encyclopedia


Anidulafungin Brand names: Eraxis™ Chemical formula: Drug Forms: Anidulafungin injection (below) Anidulafungin Solution for injection Español: Anidulafungin: Information from Answers.com


Anidulafungin has oral and intravenous formulations and has recently been licensed for development as a parenteral agent. Anidulafungin


All about Anidulafungin. View complete and up to date Anidulafungin information - part of the Drugs.com trusted medication database. Anidulafungin Facts and Comparisons at Drugs.com


Learn about the prescription medication Eraxis (Anidulafungin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Eraxis (Anidulafungin) Drug Information: Uses, Side Effects, Drug ...


Mean (%CV) Steady State Pharmacokinetic Parameters of Anidulafungin Following IV Administration of Anidulafungin Once Daily for 10 Days in Healthy Adult Subjects Anidulafungin IV ... [INTRAVENOUS INFUSION] (not for IV Bolus Injection)


Anidulafungin is a prescription drug used to treat certain fungal infections caused by the yeast Candida. It belongs to a family of drugs known as echinocandins. Other members of ... Anidulafungin - Medpedia


anidulafungin, a systemic, antifungal agent. indications This drug is used to treat Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis. anidulafungin - definition of anidulafungin in the Medical ...


Neither DoctorFungus Corporation nor its editorial staff can be held responsible for errors or for any consequences arising from the use of the information in this website. Legal Stuff


Anidulafungin professional patient advice. Specific and up to date information about Anidulafungin. Complete Anidulafungin information from Drugs.com





Featured Reviews

Reviews Bacteriostatic Water

Bacteriostatic Water Drug Description BACTERIOSTATIC WATER for Injection, USP Multiple-dose Plastic Vial WARNING NOT FOR USE IN NEONATES. DRUG DESCRIPTION The following preparation is designed solely for parenteral use only after...
Read More  |  Review This
Reviews Hydrocodone Bitartrate and Acetaminophen Tablets

Lortab 2.5 Drug Description LORTAB® 2.5/500 (hydrocodone bitartrate and acetaminophen) Tablets, USP 2.5 mg /500 mg DRUG DESCRIPTION Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration. WARNING:...
Read More  |  Review This
Reviews Halog Cream

Halog Cream Drug Description HALOG® (halcinonide) Cream, USP 0.1% For Topical Use Only. Not For Ophthalmic Use. DRUG DESCRIPTION What are the possible side effects of halcinonide topical (Halog, Halog-E)? Get emergency...
Read More  |  Review This
Reviews Clinoril

Clinoril Drug Description CLINORIL® (sulindac) Tablets Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk...
Read More  |  Review This
Reviews Nystatin Topical

Nystop Drug Description Nystop® (nystatin) Topical Powder USP For topical use only. Not for ophthalmic use. DRUG DESCRIPTION What are the possible side effects of nystatin topical (Mycostatin Topical, Nystop, Pedi-Dri)? Get...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....